• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

探索灵芝提取物粉末中多糖和益生菌作为固体载体在槲皮素液体制剂开发中的作用:一项新的研究。

Exploring role of polysaccharides present in Ganoderma lucidium extract powder and probiotics as solid carriers in development of liquisolid formulation loaded with quercetin: A novel study.

机构信息

School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab 144411, India.

School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab 144411, India.

出版信息

Int J Biol Macromol. 2021 Jul 31;183:1630-1639. doi: 10.1016/j.ijbiomac.2021.05.064. Epub 2021 May 17.

DOI:10.1016/j.ijbiomac.2021.05.064
PMID:34015408
Abstract

Ganoderma lucidium extract powder (GLEP) contains various polysaccharides which are well known for their antioxidant and anti-inflammatory actions. Probiotics (PB) are well-established for providing a plethora of health benefits. Hence, use of mushroom polysaccharides and probiotics as carriers to solidify liquisolid formulation is anticipated to function as functional excipients i.e. as adsorbent that may provide therapeutic benefits. Quercetin (QUR) has been used as model lipophilic drug in this study. QUR loaded liquisolid compacts (LSCs) were formulated using Tween 80 as solvent. These were further solidified using a combination of PB and GLEP as carriers. Aerosil-200 (A-200) was used as coating agent. The formulation exhibited very good flow characteristics. Dissolution rate of raw QUR was found to be less than 10% in 60 min while in case of QUR loaded LSCs, more than 90% drug release was observed within 5 min. Absence of crystalline peaks of QUR in the DSC and PXRD reports of LSCs and their porous appearance in SEM micrographs indicate that QUR was successfully incorporated in the LSCs. The developed formulation was found to be stable on storage under accelerated stability conditions.

摘要

灵芝提取物粉末(GLEP)含有多种多糖,其抗氧化和抗炎作用是众所周知的。益生菌(PB)被广泛认为具有多种健康益处。因此,使用蘑菇多糖和益生菌作为载体来固化液固体制剂有望作为功能性赋形剂,即作为吸附剂,可能提供治疗益处。槲皮素(QUR)已在本研究中用作亲脂性药物模型。使用吐温 80 作为溶剂来制备载有 QUR 的液固复合物(LSCs)。然后使用 PB 和 GLEP 的组合作为载体将其固化。Aerosil-200(A-200)用作包衣剂。该制剂表现出非常好的流动特性。在 60 分钟内,原始 QUR 的溶出率发现低于 10%,而在载有 QUR 的 LSCs 的情况下,在 5 分钟内观察到超过 90%的药物释放。在 LSCs 的 DSC 和 PXRD 报告中没有 QUR 的结晶峰,并且在 SEM 显微照片中它们呈现多孔外观,表明 QUR 已成功掺入 LSCs 中。在加速稳定性条件下储存时,所开发的制剂被发现稳定。

相似文献

1
Exploring role of polysaccharides present in Ganoderma lucidium extract powder and probiotics as solid carriers in development of liquisolid formulation loaded with quercetin: A novel study.探索灵芝提取物粉末中多糖和益生菌作为固体载体在槲皮素液体制剂开发中的作用:一项新的研究。
Int J Biol Macromol. 2021 Jul 31;183:1630-1639. doi: 10.1016/j.ijbiomac.2021.05.064. Epub 2021 May 17.
2
Development of mushroom polysaccharide and probiotics based solid self-nanoemulsifying drug delivery system loaded with curcumin and quercetin to improve their dissolution rate and permeability: State of the art.基于蘑菇多糖和益生菌的载姜黄素和槲皮素固体自纳米乳化药物递送系统的开发以提高其溶解速率和渗透性:现状
Int J Biol Macromol. 2021 Oct 31;189:744-757. doi: 10.1016/j.ijbiomac.2021.08.170. Epub 2021 Aug 28.
3
Self-nanoemulsifying composition containing curcumin, quercetin, Ganoderma lucidum extract powder and probiotics for effective treatment of type 2 diabetes mellitus in streptozotocin induced rats.含有姜黄素、槲皮素、灵芝提取物粉末和益生菌的自微乳组合物,用于有效治疗链脲佐菌素诱导的大鼠 2 型糖尿病。
Int J Pharm. 2022 Jan 25;612:121306. doi: 10.1016/j.ijpharm.2021.121306. Epub 2021 Nov 20.
4
Exploring role of probiotics and Ganoderma lucidum extract powder as solid carriers to solidify liquid self-nanoemulsifying delivery systems loaded with curcumin.探讨益生菌和灵芝提取物粉末作为固体载体来固化负载姜黄素的液体自微乳化给药系统的作用。
Carbohydr Polym. 2020 Dec 15;250:116996. doi: 10.1016/j.carbpol.2020.116996. Epub 2020 Aug 29.
5
Formulation Development of Mirtazapine Liquisolid Compacts: Optimization Using Central Composite Design.米氮平液固体制剂的研制:利用中心复合设计进行优化。
Molecules. 2022 Jun 22;27(13):4005. doi: 10.3390/molecules27134005.
6
Suitability of various excipients as carrier and coating materials for liquisolid compacts.各种辅料作为载体和包衣材料用于液固压缩片的适用性。
Drug Dev Ind Pharm. 2011 Oct;37(10):1200-7. doi: 10.3109/03639045.2011.564184. Epub 2011 Mar 31.
7
Development of Itraconazole Liquisolid Compact: Effect of Polyvinylpyrrolidone on the Dissolution Properties.伊曲康唑液固复合制剂的研制:聚乙烯吡咯烷酮对溶出特性的影响
Curr Drug Deliv. 2016;13(3):452-61. doi: 10.2174/1567201813666160216144323.
8
Co-encapsulated resveratrol and quercetin in chitosan and peg modified chitosan nanoparticles: For efficient intra ocular pressure reduction.壳聚糖和聚乙二醇修饰壳聚糖纳米粒共包封白藜芦醇和槲皮素:用于有效降低眼内压。
Int J Biol Macromol. 2017 Nov;104(Pt B):1837-1845. doi: 10.1016/j.ijbiomac.2017.04.117. Epub 2017 May 1.
9
Formulation factors affecting the release of ezetimibe from different liquisolid compacts.影响不同固体分散体中依泽替米贝释放的制剂因素。
Pharm Dev Technol. 2013 Mar-Apr;18(2):417-27. doi: 10.3109/10837450.2012.680594. Epub 2012 Apr 24.
10
Formulation and evaluation of liquisolid compacts for olmesartan medoxomil.奥美沙坦酯液固复合制剂的处方设计与评价
J Drug Deliv. 2013;2013:870579. doi: 10.1155/2013/870579. Epub 2013 Oct 21.

引用本文的文献

1
Enhancing the oral bioavailability of fisetin: polysaccharide-based self nano-emulsifying spheroids for colon-targeted delivery.增强非瑟酮的口服生物利用度:基于多糖的自微乳化球体用于结肠靶向递药。
Drug Deliv Transl Res. 2024 Oct;14(10):1-17. doi: 10.1007/s13346-024-01634-6. Epub 2024 May 24.
2
Multivariate Data Analysis and Central Composite Design-Oriented Optimization of Solid Carriers for Formulation of Curcumin-Loaded Solid SNEDDS: Dissolution and Bioavailability Assessment.基于多变量数据分析和中心复合设计的姜黄素固体自乳化药物传递系统固体载体优化:溶出度和生物利用度评估
Pharmaceutics. 2022 Nov 6;14(11):2395. doi: 10.3390/pharmaceutics14112395.
3
Expanding Arsenal against Neurodegenerative Diseases Using Quercetin Based Nanoformulations: Breakthroughs and Bottlenecks.
利用槲皮素纳米制剂对抗神经退行性疾病的武器库不断扩大:突破与瓶颈。
Curr Neuropharmacol. 2023;21(7):1558-1574. doi: 10.2174/1570159X20666220810105421.